Glutamate-based therapeutic approaches: NR2B receptor antagonists.
about
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateStructure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunitGlutamate receptor ion channels: structure, regulation, and functionIdentification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screeningFear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageingSpider venoms: a rich source of acylpolyamines and peptides as new leads for CNS drugs.Receptor-Based Discovery of a Plasmalemmal Monoamine Transporter Inhibitor via High Throughput Docking and Pharmacophore Modeling.Neuropathological responses to chronic NMDA in rats are worsened by dietary n-3 PUFA deprivation but are not ameliorated by fish oil supplementation.A series of structurally novel heterotricyclic alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor-selective antagonists.An autosomal recessive leucoencephalopathy with ischemic stroke, dysmorphic syndrome and retinitis pigmentosa maps to chromosome 17q24.2-25.3.Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders.Region-specific role for GluN2B-containing NMDA receptors in injury to Purkinje cells and CA1 neurons following global cerebral ischemia.Cortical NR2B NMDA subunit antagonism reduces inflammatory pain in male and female ratsNew medications for drug addiction hiding in glutamatergic neuroplasticity.Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer's diseasePromising targets of cell death signaling of NR2B receptor subunit in stroke pathogenesis.Conantokin-G attenuates detrimental effects of NMDAR hyperactivity in an ischemic rat model of stroke.Compound MQA, a Caffeoylquinic Acid Derivative, Protects Against NMDA-Induced Neurotoxicity and Potential Mechanisms In Vitro.N-methyl-D-aspartate receptor mechanosensitivity is governed by C terminus of NR2B subunit.Opposing action of conantokin-G on synaptically and extrasynaptically-activated NMDA receptors.Intersubunit interactions at putative sites of ethanol action in the M3 and M4 domains of the NMDA receptor GluN1 and GluN2B subunits.Is there hope for chronic pain and headache?Receptor and channel heteromers as pain targets.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networksEffects of chronic NMDA-NR2b inhibition in the median eminence of the reproductive senescent female rat.Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticityTargeting the NMDA receptor subunit NR2B for the treatment of neuropathic painCurrent approaches with the glutamatergic system as targets in the treatment of neuropathic pain.Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potentialSynaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapseRole of spinal neurotransmitter receptors in itch: new insights into therapies and drug development.Neuronal and microglial mechanisms of neuropathic painInvestigational NMDA receptor modulators for depression.Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulatorsPharmacokinetic and pharmacodynamic considerations for NMDA receptor antagonists in the treatment of chronic neuropathic pain.Ephrins and pain.NMDA Receptor Activity in Neuropsychiatric Disorders.NMDA Receptors in Glial Cells: Pending Questions.Ion channel therapeutics for pain.miR-137, a new target for post-stroke depression?
P2860
Q27004490-9C773F53-6C0D-4832-8474-14F4542DF3DAQ27658149-69C0FA04-9FA9-4642-B365-E81B6C7A1F85Q28290774-5CDE573E-5E93-43B1-81DA-F88CCD0EEDA5Q28538569-79A672CD-79B6-4471-9EF4-B777DB2B47B8Q30484426-C01A6066-AF59-41E2-B739-F277BDE07480Q33271332-0DDFF4A0-D39A-42F0-B5B4-17D16F62A117Q33547418-B88B9D8A-CDF1-4569-B9D9-2B5F0C1F8219Q33567704-AF45108F-1691-4C3B-9F0D-B1DE7EED809CQ34124829-749A1974-857B-490A-A43F-5DAB748F4331Q34204971-06817E6E-B73B-4C34-9176-9FF8CB7A60B9Q34233293-717DCDF8-499D-4982-8D52-6350B59A7CCBQ34714442-B6888687-08E5-43B7-8445-8D4B4906D8BEQ35328079-333FFFDD-7DC4-4176-9B72-DCAEDCF00A55Q35333393-AB810AEC-4152-4076-9982-BFE20297624FQ35569999-F5E44922-11B5-4FCB-BCF4-57B437655F67Q35576381-F3160DA8-69DE-41D3-8B5A-A280C88DC001Q35589910-2703F11B-C157-4755-84E4-027D80142AFFQ35669940-F9A3D8BC-6E8B-41A4-BC0F-54258516B5F3Q35763200-12C678B5-F01D-4D95-8893-8CBE3341CA9AQ36923095-46C04A79-7580-4E8C-B945-3F2D3F9C4F7FQ36941272-7501F984-114E-40BC-BFDB-8E0FDA3B7B26Q36947170-032E0305-BC6D-4833-AC28-41144081DCF0Q37148710-164EE88A-3B4B-4948-96BA-B7A7759B3B3AQ37220392-913C24BC-DC85-4AC5-8E75-4C315432A1A0Q37239924-6DE0AA87-35CD-455B-AFB0-9295BB99A7AAQ37333350-6DB351A7-1026-4593-9B8A-EAB061CCC548Q37374352-2969760E-0232-4B8B-815A-051D00A34EA2Q37523991-3787B9D8-CDDA-435E-B90B-C3DC6C25A3D1Q37548763-3C2B85AA-F080-48AE-986C-4FCD39F96EF7Q37705513-FD932F01-55F2-425A-9448-3FBF2D96B80AQ37800506-C4C4EDF5-B555-4832-97BE-651734139E2AQ37908201-7E8E31D7-BC72-4F37-AAFC-3AD4F3D80E14Q37957965-F7C21F23-921B-4D31-9A20-CA7279D2CE8CQ37978091-3050E550-5D7E-4193-9D56-86BB129C2D19Q38032607-64EDABB2-FC01-4C3F-B519-4D6002124E59Q38112820-F1CB8EF3-C19F-4F1F-98F7-DD523FB13CB1Q38114881-15B07631-060A-439A-AA7A-1E9C1E8B5B8DQ38157889-B8690CCB-4AC8-4C6B-A51B-8E8E46753B71Q38556040-E69712E3-F3B6-4743-84CA-29D1E0105BBBQ38957856-1112A32A-BE03-4F30-8EB6-1C96BD2E1BCF
P2860
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@ast
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@en
type
label
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@ast
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@en
prefLabel
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@ast
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@en
P1476
Glutamate-based therapeutic approaches: NR2B receptor antagonists.
@en
P2093
Kathleen R Gogas
P356
10.1016/J.COPH.2005.11.001
P577
2005-12-22T00:00:00Z